News

Diagnosis: model beats doctor
Enlarge image

ResearchNetherlandsSwitzerland

Diagnosis: model beats doctor

22.04.2013 - Computers are better than doctors at predicting the outcomes and responses of lung cancer patients to treatment, say Dutch researchers.

The team around Cary Oberije presented its findings at the 2nd Forum of the European Society for Radiotherapy and Oncology (ESTRO) in Geneva. They said the model’s predictions remained superior to those of doctors even after the latter had seen the patient. The models use genomic information from previous patients to create a statistical formula that can be used to predict the probability of outcome and responses to treatment using radiotherapy with or without chemotherapy for future patients.

Having obtained predictions from the mathematical models, the researchers asked experienced radiation oncologists to predict the likelihood of lung cancer patients surviving for two years, or suffering from shortness of breath (dyspnea) and difficulty swallowing (dysphagia) at two points in time: 1) after they had seen the patient for the first time, and 2) after the treatment plan was made. At the first time point, the doctors predicted two-year survival for 121 patients, dyspnea for 139 and dysphagia for 146 patients. At the second time point, predictions were only available for 35, 39 and 41 patients respectively.

For all three predictions and at both time points, the mathematical models substantially outperformed the doctors' predictions, with the doctors' predictions being little better than those expected by chance.The researchers plotted the results on a special graph [1] on which the area below the plotted line is used for measuring the accuracy of predictions; 1 represents a perfect prediction, while 0.5 represents predictions that were right in 50% of cases, i.e. the same as chance. They found that the model predictions at the first time point were 0.71 for two-year survival, 0.76 for dyspnea and 0.72 for dysphagia. In contrast, the doctors' predictions were 0.56, 0.59 and 0.52 respectively.

"The number of treatment options available for lung cancer patients are increasing, as well as the amount of information available to the individual patient. It is evident that this will complicate the task of the doctor in the future," said Dr. Oberije from Maastricht University Medical Center. "If models based on patient, tumour and treatment characteristics already out-perform the doctors, then it is unethical to make treatment decisions based solely on the doctors' opinions. We believe models should be implemented in clinical practice to guide decisions."

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-02/diagnosis-computer-beats-doctor.html

BusinessUK

03.03.2015 After weeks of speculation, AstraZeneca has announced its plans to spin out its early-stage antibiotic R&D. The decision marks the company’s aims to “sharpen its focus on three main therapy areas”.

GenericsEUUKHungaryGermanyItalyGreeceAustriaLuxembourgFranceSpain

26.02.2015 It is the first biosimilar monoclonal antibody in many European markets: Mundipharma and Hospira are launching Celltrion’s Remicade generic.

M&AUK

23.02.2015 British drug developer Heptares has been acquired by Japanese biopharma play Sosei for US$400m (€352m).

bioethanolGermanyUKBelgiumFrance

19.02.2015 The price of oil has been sliding for months, and the European bioethanol market is taking it hard. CropEnergies AG has now stopped production at its British unit Ensus UK.

BusinessFranceGermany

17.02.2015 After Christopher Viehbacher’s unceremonious ousting last year, Sanofi has been on the look out for a new CEO. Now, sources say Bayer’s Olivier Brandicourt is set to fill the position.

BusinessUKSwitzerland

12.02.2015 Glaxosmithkline is intent on bolstering its vaccine portfolio further and has bought all shares of Swiss development partner Glycovaxyn.

InvestmentsUKEU

10.02.2015 Interest in biotechnology is on the rise among British investors. Not just one, but two major financiers are planning investment funds in the field.

IVFUKEU

04.02.2015 In a historic move, the UK is set to become the first country to allow the creation of babies with the genetic material of three people – a mother, a father and a female mitochondrial donor.

Events

All Events

Partner-Events

Planegg/Martinsried

1st Munich Biotech Pitch

Berlin (DE)

Proteomic Forum 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • MEDIGENE4.64 EUR7.16%
  • FORMYCON16.89 EUR4.07%
  • BIOFRONTERA1.99 EUR3.65%

FLOP

  • HBM102.00 CHF-2.86%
  • SYNGENTA327.00 CHF-2.15%
  • STRATEC BIOMEDICAL45.12 EUR-2.10%

TOP

  • WILEX3.17 EUR48.8%
  • EVOLVA1.70 CHF18.9%
  • MEDIGENE4.64 EUR16.6%

FLOP

  • MOLOGEN5.25 EUR-14.1%
  • SANTHERA98.45 CHF-10.3%
  • 4SC0.77 EUR-9.4%

TOP

  • SANTHERA98.45 CHF2457.1%
  • WILEX3.17 EUR403.2%
  • FORMYCON16.89 EUR115.7%

FLOP

  • CYTOS0.37 CHF-86.9%
  • MOLOGEN5.25 EUR-57.4%
  • PAION2.10 EUR-55.3%

No liability assumed, Date: 04.03.2015